Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
暂无分享,去创建一个
Cheryl Jorcyk | Nianqing Xiao | Carolyn J M Best | Michael R Emmert-Buck | M. Emmert-Buck | N. Xiao | Carolyn J. M. Best | J. Kang | Jeffrey E. Green | A. Calvo | C. Jorcyk | Jeffrey E Green | Isabel M Leiva | Alfonso Calvo | Jason Kang | Isabel Leiva
[1] J. Köllermann,et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. , 2001, American journal of clinical pathology.
[2] T. H. van der Kwast,et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.
[3] Bruce W. Turnbull,et al. Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .
[4] C. Wild,et al. A critical evaluation of the application of biomarkers in epidemiological studies on diet and health , 2001, British Journal of Nutrition.
[5] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[6] F. Hamdy,et al. Localization and quantification of mRNA for matrix metalloproteinase‐2 (MMP‐2) and tissue inhibitor of matrix metalloproteinase‐2 (TIMP‐2) in human benign and malignant prostatic tissue , 1997, The Prostate.
[7] O. Cussenot,et al. htert expression correlates with MYC over‐expression in human prostate cancer , 2000, International journal of cancer.
[8] Y. Surh,et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. , 2001, Mutation research.
[9] T. Stamey,et al. Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone , 1986, The Prostate.
[10] M. Shen,et al. Molecular genetics of prostate cancer. , 2000, Genes & development.
[11] M. Shibata,et al. Development and characterization of a mouse prostate adenocarcinoma cell line: Ductal formation determined by extracellular matrix , 1998, The Prostate.
[12] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[13] J. Arthur,et al. Selenium, selenoproteins and human health: a review , 2001, Public Health Nutrition.
[14] T. Flam,et al. Epidemiology of Prostatic Cancer , 1990, The Journal of international medical research.
[15] K. Mita,et al. Expression of the insulin‐like growth factor system and cancer progression in hormone‐treated prostate cancer patients , 2000, International journal of urology : official journal of the Japanese Urological Association.
[16] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Morrow,et al. Pathogenesis of diquat‐induced liver necrosis in selenium‐deficient rats: Assessment of the roles of lipid peroxidation and selenoprotein P , 1995, Hepatology.
[18] W. Isaacs,et al. The cadherin cell-cell adhesion pathway in prostate cancer progression. , 1997, British journal of urology.
[19] H. Klocker,et al. Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.
[20] O. Kallioniemi,et al. ANX7, a candidate tumor suppressor gene for prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Clark,et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. , 2001, Cancer research.
[22] Schr,et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.
[23] R. Hurst,et al. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma , 2000, Cancer.
[24] G. MacLennan,et al. Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice , 2000 .
[25] A. Montgomery,et al. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. , 2001, Molecular biology of the cell.
[26] M. Arenas,et al. E-, N- And P-cadherin, and α-, β- and γ-catenin Protein Expression in Normal, Hyperplastic and Carcinomatous Human Prostate , 2000, The Histochemical Journal.
[27] K. Griffiths,et al. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. , 1996, British Journal of Cancer.
[28] Jeffrey E. Green,et al. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. , 2002, Neoplasia.
[29] M. Webber,et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression , 2001, The Prostate.
[30] S. Garrett,et al. Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.
[31] K. Matsusue,et al. Characterization of mouse metastasis-associated gene 2: genomic structure, nuclear localization signal, and alternative potentials as transcriptional activator and repressor. , 2001, DNA and cell biology.
[32] C. Wood,et al. Tumor-suppressive activity of CD66a in prostate cancer , 1999, Cancer Gene Therapy.
[33] W. Almers,et al. Annexin 2 has an essential role in actin-based macropinocytic rocketing , 2001, Current Biology.
[34] N. Scollan,et al. In vivo measurement of lipogenesis in ruminants using [1-(14)C]acetate. , 2001, The British journal of nutrition.
[35] R. Burk,et al. Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diquat administration. Effect of selenium deficiency. , 1980, The Journal of clinical investigation.
[36] A. Tsang,et al. Expression and characterization of a dictyostelium discoideum annexin , 1994, Molecular and Cellular Biochemistry.
[37] A. Scorilas,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer , 2022 .
[38] G. Haas,et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.
[39] J. Cheville,et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] J. Green,et al. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. , 2001, Cancer research.
[41] B W Turnbull,et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. , 1996, JAMA.
[42] C. Sheehan,et al. Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. , 2001, Human pathology.
[43] C. Cordon-Cardo,et al. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] J. Ward,et al. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. , 1996, Cancer research.
[45] E. Constant,et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. , 1998 .